Jazz Pharmaceuticals, Inc.

NASDAQ: JAZZ
$141.83
-$1.00 (-0.7%)
Closing price November 25, 2020
A recent research piece from the biotech analysts at Stifel focused on three top stocks to buy with outstanding potential.
The analysts at Piper Jaffray are very positive on four top specialty pharmaceutical stocks with potential for a strong fourth-quarter rally in their shares.
Cowen asked the analysts which stocks should be on their shopping lists. Here are the six with the biggest upside potential.
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
These are the top analyst upgrades and downgrades from 24/7 Wall St. on Tuesday, August 19. 2004. They include Applied Materials, Pollo Loco, Dollar General, SolarCity and Urban Outfitters.
Source: ThinkstockEvery time the economy gets good again, and every time the stock market gets high again, waves of mergers and acquisitions begin taking place. The stock market’s bull run is now...
St. Patrick's Day may have come and gone for this year, but the analysts at biotech boutique shop Leerink have highlighted six Ireland-based firms that could be tempting takeover targets for large...
In a new research report, the boutique firm Leerink highlights 10 top biotech names that are strong candidates for a partnership or acquisition. Any of these picks may be a great addition for...
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Friday, March 7, 2014. They include Nokia, Safeway, Sirius XM, Skull Candy and Teva...
Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report shows which companies they believe will make acquisitions or which will be...
The new year is well under way and the major firms on Wall Street are all presenting their best stock ideas for 2014. The team at Cantor Fitzgerald is no exception.
Source: Jon OggStocks have pulled back marginally but are still close to all-time highs. We are sliding into year-end, and investors are trying to position themselves for 2014 and beyond. 24/7 Wall...
Source: ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you look...
Source: Thinkstock24/7 Wall St. is looking for the next great biotech stocks for 2013 after great gains have been seen in 2012. If you look at the consensus price targets from analysts for the coming...
The three major U.S. stock indexes opened lower this morning on the absence of any big macroeconomic data in Asia or Europe. Tensions between China and Japan over a handful of islands in the East...